Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2014

Open Access 01-12-2014 | Research

Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study

Authors: Mick Serpell, Adam Gater, Stuart Carroll, Linda Abetz-Webb, Azharul Mannan, Robert Johnson

Published in: Health and Quality of Life Outcomes | Issue 1/2014

Login to get access

Abstract

Background

Post-herpetic neuralgia (PHN) is the most common complication of herpes zoster (shingles). As a chronic condition, PHN can have a substantial adverse impact on patients’ lives. However, UK-specific data concerning the burden of PHN on individual patients, healthcare systems and wider society, are lacking. As the first UK-wide cross-sectional study of its kind, The Zoster Quality of Life (ZQOL) study was designed to address these concerns.

Methods

Patients (n = 152) with a confirmed diagnosis of PHN (defined as pain persisting ≥ 3 months following rash onset) and aged ≥50 years were recruited from primary and secondary/tertiary care centres throughout the UK. All patients completed validated questionnaires, including the Zoster Brief Pain Inventory (ZBPI), the Medical Outcomes Study Short-Form 36 (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Treatment Satisfaction with Medication (TSQM) questionnaire. Where available, mean patient population scores on these questionnaires were compared to scores derived from age-matched normative samples to quantify the burden associated with PHN.

Results

Despite numerous consultations with healthcare professionals and receiving multiple medications for the management of their PHN, the majority of patients reported being in pain ‘most of the time’ or ‘all of the time’. A total of 59.9% (n = 91) of all PHN patients reported pain in the preceding 24 hours to assessment at levels (ZBPI worst pain ≥ 5) typically considered to have a significant impact on Health Related Quality of Life (HRQoL). Accordingly, scores for SF-36 and EQ-5D indicated significant deficits in HRQoL among PHN patients compared to age-matched norms (p < 0.05) and patients reported being dissatisfied with the perceived efficacy of therapies received for the management of PHN. Increased pain severity was observed among older participants and higher levels of pain severity were associated with greater HRQoL deficits.

Conclusions

The inadequate relief provided by PHN therapies available in the UK is associated with a significant burden among PHN patients in terms of pain severity and deficits in HRQoL which may persist for years. Therefore, alternative means such as prevention of shingles and PHN, are essential for reducing the impact on individual patients, healthcare systems and society as a whole.
Appendix
Available only for authorised users
Literature
1.
Brisson M, Edmunds WJ: Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003, 70(Suppl 1):S9–14.CrossRefPubMed
2.
Schmader K, Gnann JW, Watson CP: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008, 197: S207-S215. 10.1086/522152CrossRefPubMed
3.
Pinchinat S, Cebrian-Cuenca A, Bricout H, Johnson R: Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013, 13: 170. 10.1186/1471-2334-13-170PubMedCentralCrossRefPubMed
4.
Johnson RW, Wasner G, Saddier P, Baron R: Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007, 7: 1581–1595. 10.1586/14737175.7.11.1581CrossRefPubMed
5.
Dworkin RH, Schmader KE: The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In Herpes zoster and postherpetic neuralgia. 2nd edition. Amsterdam: Elsevier; 2001:39–64.
6.
Mick G, Hans G: Postherpetic neuralgia in Europe: the scale of the problem and outlook for the future. Journal of Clinical Gerontology and Geriatrics 2013, 4: 102–108. 10.1016/j.jcgg.2013.03.001CrossRef
7.
van Seventer R, Sadosky A, Lucero M, Dukes E: A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35: 132–137. 10.1093/ageing/afj048CrossRefPubMed
8.
Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA: Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000, 321: 794. 10.1136/bmj.321.7264.794PubMedCentralCrossRefPubMed
9.
Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R: Risk factors for postherpetic neuralgia. Arch Intern Med 1997, 157: 1217–1224. 10.1001/archinte.1997.00440320117011CrossRefPubMed
10.
Coen PG, Scott F, Leedham-Green M, Nia T, Jamil A, Johnson RW, Breuer J: Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice? Eur J Pain 2006, 10: 695–700. 10.1016/j.ejpain.2005.11.002CrossRefPubMed
11.
Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA: The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Canadian Medical Association Journal 2010, 182: 1731–1736. 10.1503/cmaj.091711PubMedCentralCrossRefPubMed
12.
Bowsher D: The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999, 3: 335–342. 10.1016/S1090-3801(99)90015-0CrossRefPubMed
13.
Gauthier A, Breuer J, Carrington D, Martin M, Remy V: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137: 38–47. 10.1017/S0950268808000678CrossRefPubMed
14.
Chidiac C, Bruxelle J, Daures J-P, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, de Labareyre C: Characteristics of Patients with Herpes Zoster on Presentation to Practitioners in France. Clinical Infectious Diseases 2001, 33: 62–69. 10.1086/320884CrossRefPubMed
15.
Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD: Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. The journal of pain: official journal of the American Pain Society 2005, 6(6):356–363. 10.1016/j.jpain.2005.01.359CrossRef
16.
Brisson M, Pellissier JM, Camden S, Quach C, De WP: The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008, 4: 238–245. 10.4161/hv.4.3.5686CrossRefPubMed
17.
Cebrian-Cuenca AM, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J: Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis 2011, 11: 302. 10.1186/1471-2334-11-302PubMedCentralCrossRefPubMed
18.
Dworkin RH, White R, O’Connor AB, Baser O, Hawkins K: Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007, 55: 1168–1175. 10.1111/j.1532-5415.2007.01231.xCrossRefPubMed
19.
Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV: Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010, 11: 360–368. 10.1016/j.jpain.2009.08.005CrossRefPubMed
20.
Rothberg MB, Virapongse A, Smith KJ: Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44: 1280–1288. 10.1086/514342CrossRefPubMed
21.
Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O: Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 2013, 14(6):1015–1026. 10.1007/s10198-012-0452-1CrossRefPubMed
22.
Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J: The burden of herpes zoster: a prospective population based study. Vaccine 2006, 24: 1308–1314. 10.1016/j.vaccine.2005.09.026CrossRefPubMed
23.
Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75: 800–802. 10.1093/biomet/75.4.800CrossRef
24.
Lancaster T, Silagy C, Gray S: Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995, 45: 39–45.PubMedCentralPubMed
25.
Volpi A, Gatti A, Serafini G, Costa B, Suligoi B, Pica F, Marsella LT, Sabato E, Sabato AF: Clinical and psychosocial correlates of acute pain in herpes zoster. Journal of Clinical virology: the Official publication of the Pan American Society for Clinical Virology 2007, 38: 275–279. 10.1016/j.jcv.2007.01.010CrossRef
26.
Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. The Journal of pain: Official Journal of the American Pain Society 2004, 5: 344–356. 10.1016/j.jpain.2004.06.001CrossRef
27.
Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ: Pain and Its Treatment in Outpatients with Metastatic Cancer. New England Journal of Medicine 1994, 330: 592–596. 10.1056/NEJM199403033300902CrossRefPubMed
28.
Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan ISF, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN: The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults. The Clinical Journal of Pain 2007, 23: 490–496. 10.1097/AJP.0b013e318065b6c9CrossRefPubMed
29.
Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care 1992, 30: 473–483. 10.1097/00005650-199206000-00002CrossRefPubMed
30.
Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH: Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004, 39: 342–348. 10.1086/421942CrossRefPubMed
31.
Ware JE Jr: SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25: 3130–3139. 10.1097/00007632-200012150-00008CrossRef
32.
Rabin R, de CF: EQ-5D: a measure of health status from the EuroQol group. Ann Med 2001, 33: 337–343. 10.3109/07853890109002087CrossRefPubMed
33.
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR: Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2: 12. 10.1186/1477-7525-2-12PubMedCentralCrossRefPubMed
34.
35.
36.
SF-36 v2 US population norms. Lincoln: QualityMetric Incorporated; 1998.
37.
Kind P, Hardman G, Macran S: UK population norms for EQ-5D. York: Centre for Health Economics, University of York. Working Papers; 1999.
38.
Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, Clinical Significance Consensus Meeting Group: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77: 371–383. 10.4065/77.4.371CrossRefPubMed
39.
Sloan JA, Cella D, Hays RD: Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005, 58(12):1217–1219. 10.1016/j.jclinepi.2005.07.009CrossRefPubMed
40.
Wyrwich KW, Tierney WM, Wolinsky FD: Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52(9):861–873. 10.1016/S0895-4356(99)00071-2CrossRefPubMed
41.
Hurley RW, Adams MCB: Sex, gender, and pain: an overview of a complex field. Anesthesia & Analgesia 2008, 107: 309–317. 10.1213/01.ane.0b013e31816ba437CrossRef
42.
Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? grading pain severity by its interference with function. Pain 1995, 61: 277–284. 10.1016/0304-3959(94)00178-HCrossRefPubMed
43.
World Health Organization: Traitement de la douleur cancéreuse. Geneva, Switzerland: World Health Organization; 1987.
44.
Cleeland C: Measurement of pain by subjective report. Advances in Pain Research and Therapy 1989, 12: 391–403.
45.
Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson RW: Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. 2014.
46.
Jung BF, Johnson RW, Griffin DR, Dworkin RH: Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004, 62: 1545–1551. 10.1212/01.WNL.0000123261.00004.29CrossRefPubMed
47.
Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF: Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008, 80: 1646–1652. 10.1002/jmv.21254CrossRefPubMed
48.
Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, Clark MR, Raja SN: Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology 2000, 92: 691–698. 10.1097/00000542-200003000-00013CrossRefPubMed
49.
Buonocore M, Gatti AM, Amato G, Aloisi AM, Bonezzi C: Allodynic skin in post-herpetic neuralgia: Histological correlates. Journal of Cellular Physiology 2012, 227: 934–938. 10.1002/jcp.22804CrossRefPubMed
50.
Obidoa CA, Reisine SL, Cherniack M: How does the SF-36 perform in healthy populations? a structured review of longitudinal studies. Journal of Social, Behavioral, and Health Sciences 2010., 1:
51.
Johnson RW, Griffiths P: Global strategies to prevent herpes zoster and its associated complications. Herpes 2007, 14(2):24.PubMed
52.
Schmader K: Treatment and prevention strategies for herpes zoster and postherpetic neuralgia in older adults. Clin Geriatrics 2006, 14: 26–33.
53.
Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpää ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Langston DP, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, Sijck AJMV, Wallace MS, Wassilew SW, Whitley RJ: Recommendations for the management of herpes zoster. Clinical Infectious Diseases 2007, 44: S1–26. 10.1086/510206CrossRefPubMed
54.
Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ: Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39: 1546–1553. 10.1128/AAC.39.7.1546PubMedCentralCrossRefPubMed
55.
Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ: Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000, 9: 863–869. 10.1001/archfami.9.9.863CrossRefPubMed
56.
Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L: Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009, 2: 2.
57.
Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L: Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009, 2: 2.
58.
59.
Carroll S, Gater A, Abetz-Webb L, Smith F, Demuth D, Mannan A: Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the zoster quality of life (ZQOL) study. BMC Res Notes 2013, 6: 486. 10.1186/1756-0500-6-486PubMedCentralCrossRefPubMed
60.
Dworkin RH: Racial differences in herpes zoster and age at onset of varicella. J Infect Dis 1996, 174: 239–241. 10.1093/infdis/174.1.239CrossRefPubMed
61.
Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD: Racial differences in the occurrence of herpes zoster. J Infect Dis 1995, 171: 701–704. 10.1093/infdis/171.3.701CrossRefPubMed
62.
Talukder YS, Kafatos G, Pinot de MOIRA A, Aquilina J, Parker SP, Crowcroft NS, Brown DWG, Breuer J: The seroepidemiology of varicella zoster virus among pregnant Bangladeshi and white British women in the London Borough of Tower Hamlets, UK. Epidemiology & Infection 2007, 135: 1344–1353.CrossRef
Metadata
Title
Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the zoster quality of life (ZQOL) study
Authors
Mick Serpell
Adam Gater
Stuart Carroll
Linda Abetz-Webb
Azharul Mannan
Robert Johnson
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2014
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-12-92

Other articles of this Issue 1/2014

Health and Quality of Life Outcomes 1/2014 Go to the issue

Research

Evaluation of a skin self examination attitude scale using an item response theory model approach

Research

Instrument development and validation of the stroke pre-hospital delay behavior intention scale in a Chinese urban population

Research

Measurement invariance across chronic conditions: a systematic review and an empirical investigation of the Health Education Impact Questionnaire (heiQ™)

Research

Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population

Research

Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks

Research

Health-related quality of life in chronic obstructive pulmonary disease patients in Korea